Glotope and BoomRay have maintained a long-term strategic collaboration. The signing of the "Strategic Cooperation Framework Agreement" marks a new milestone in the collaboration. By establishing a strategic partnership, both parties aim to further strengthen their cooperation, achieve complementary advantages, innovate development, share resources for win-win outcomes.

Under the agreement, both parties will leverage their resources and business strengths to drive nuclear drug innovation. They aim to create a mutually beneficial radiopharmaceutical ecosystem focused on the radionuclide industry and drug development. This partnership will form a comprehensive and long-term strategic relationship for accurate tumor diagnosis and treatment plans. Glotope will offer BoomRay integrated services, including radionuclide supply and radiopharmaceuticals development, utilizing its nationwide production base, in-depth R&D capabilities, and extensive registration experience. Together, they will promote mutual benefits and high-quality development of innovative targeted radiopharmaceuticals in China.

Glotope’s COO Bai Ge said, "We are pleased to establish a deep strategic partnership with BoomRay. This collaboration, leveraging Glotope's advanced technology and expertise in radiopharmaceuticals development and manufacturing, will accelerate BoomRay's innovative projects, enhance competitiveness, and benefit cancer patients. We look forward to providing better services and products to our clients in the future."

BoomRay’s CEO Dr. Bo Shan said, "Since its founding, BoomRay has practiced the principles of 'innovation, cooperation, and win-win.' This strategic partnership with Glotope will strongly support our new drug development. With our partners' support, BoomRay will continue to achieve breakthroughs and contribute significantly to the global pharmaceutical and healthcare industry."